Emerging Growth Research Releases Q3 2025 Update Report on 22nd Century Group
New York, New York--(Newsfile Corp. - November 26, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), highlighting the Company's now cash-rich balance sheet, full debt repayment, settlement of a $9.5 million insurance case, and stabilization of its Contract Manufacturing Operations (CMO). The updated report also reflects management's revised outlook for EBITDA breakeven, now expected in Q3 2026.
Key Highlights from the Update Report:
For a copy of the full quarterly report, please visit:
https://emerginggrowth.com/wp-content/uploads/2025/11/XXII_Update_11.26.25.pdf
or
http://www.EmergingGrowth.com/profile/xxii/ (on the right side of the page as you scroll down)
About the Company
22nd Century Group, Inc. (NASDAQ: XXII) is a U.S.-based contract manufacturer for combustible tobacco products and the sole provider of VLN® reduced-nicotine cigarettes. With a focus on nicotine harm reduction and a stabilized CMO business, the Company is positioned to drive growth through its proprietary VLN® products while leveraging its operational capacity to scale higher-margin offerings. Founded in 1998, it is headquartered in Mocksville, NC.
Contact
Emerging Growth Research
Research@EmergingGrowth.com
www.EmergingGrowth.com
Forward-Looking Statements
This press release contains forward-looking statements, including expectations regarding EBITDA breakeven timing, anticipated CMO and VLN® revenue growth, long-term financial performance, cash utilization, and potential dilution related to warrants or preferred share conversions. Actual results may differ materially due to risks and uncertainties. Readers are encouraged to review the full disclosure and risk factors included in the complete Emerging Growth Research update report.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276032
SOURCE: Emerging Growth Research